Skip to content

CHINA PHARMA HOLDINGS, INC.: 10-Q filed 2025-11-12

What CHINA PHARMA HOLDINGS, INC. reported in its quarterly report filed 2025-11-12 (fiscal Q3 2025): 49 published measures, 146 facts as tagged in accession 0001213900-25-109203.

This filing

Form
10-Q (quarterly report)
Filed
2025-11-12
Fiscal period
fiscal Q3 2025
Accession
0001213900-25-109203 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CHINA PHARMA HOLDINGS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-3015,804,793USD
At 2024-12-3114,887,524USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-09-307,490,796USD
At 2024-12-317,139,620USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-308,313,997USD
At 2025-06-306,461,744USD
At 2025-03-316,969,848USD
At 2024-12-317,747,904USD
At 2024-09-306,528,249USD
At 2024-06-307,408,522USD
At 2024-03-318,292,154USD
At 2023-12-317,454,621USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-09-30267,625USD
At 2024-12-31626,879USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-651,482USD92
2025-01-01 to 2025-09-30-1,965,421USD273
2025-04-01 to 2025-06-30-528,367USD91
2025-01-01 to 2025-03-31-785,572USD90
2024-07-01 to 2024-09-30-1,117,911USD92
2024-01-01 to 2024-09-30-3,511,933USD274
2024-04-01 to 2024-06-30-1,438,130USD91
2024-01-01 to 2024-03-31-955,892USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-3,729USD273
2024-01-01 to 2024-09-30-704,836USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2025-01-01 to 2025-09-3058,870USD273
2024-01-01 to 2024-09-3018,866USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2025-07-01 to 2025-09-30756,217USD92
2025-01-01 to 2025-09-302,918,271USD273
2024-07-01 to 2024-09-301,100,152USD92
2024-01-01 to 2024-09-303,394,934USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-221,435USD273
2024-01-01 to 2024-09-3020,551USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-131,484USD273
2024-01-01 to 2024-09-30-18,866USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-30-45,992,100USD
At 2024-12-31-44,026,679USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-303,874,085shares92
2025-01-01 to 2025-09-303,468,211shares273
2024-07-01 to 2024-09-301,730,672shares92
2024-01-01 to 2024-09-301,559,347shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-0.17USD/shares92
2025-01-01 to 2025-09-30-0.57USD/shares273
2024-07-01 to 2024-09-30-0.65USD/shares92
2024-01-01 to 2024-09-30-2.25USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-0.17USD/shares92
2025-01-01 to 2025-09-30-0.57USD/shares273
2024-07-01 to 2024-09-30-0.65USD/shares92
2024-01-01 to 2024-09-30-2.25USD/shares274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-09-304,502,479USD
At 2024-12-314,883,401USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-628,145USD92
2025-01-01 to 2025-09-30-2,038,883USD273
2024-07-01 to 2024-09-30-1,085,257USD92
2024-01-01 to 2024-09-30-3,392,830USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-09-302,329,427USD
At 2024-12-313,270,389USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2025-07-01 to 2025-09-306,798USD92
2025-01-01 to 2025-09-3020,393USD273
2024-07-01 to 2024-09-306,843USD92
2024-01-01 to 2024-09-3020,551USD274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-09-306,622,806USD
At 2024-12-315,017,288USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2025-09-308,447,939USD
At 2024-12-316,444,480USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2025-09-30224,638USD
At 2024-12-31232,140USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-07-01 to 2025-09-30568,491USD92
2025-01-01 to 2025-09-301,756,158USD273
2024-07-01 to 2024-09-30565,608USD92
2024-01-01 to 2024-09-301,567,771USD274

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2025-09-301,649,682USD
At 2024-12-312,266,154USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-59,654USD92
2025-01-01 to 2025-09-30-282,725USD273
2024-07-01 to 2024-09-30-519,649USD92
2024-01-01 to 2024-09-30-1,825,059USD274

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2025-07-01 to 2025-09-30815,871USD92
2025-01-01 to 2025-09-303,200,996USD273
2024-07-01 to 2024-09-301,619,801USD92
2024-01-01 to 2024-09-305,219,993USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-07-01 to 2025-09-3040,321USD92
2025-01-01 to 2025-09-3090,860USD273
2024-07-01 to 2024-09-3087,610USD92
2024-01-01 to 2024-09-30283,395USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-09-303,261,911shares
At 2024-12-313,261,911shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-09-30267,625USD
At 2024-12-31626,879USD
At 2024-09-30718,691USD
At 2023-12-311,423,838USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-09-3043,076,319USD
At 2024-12-3140,631,679USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2025-09-3011,404,756USD
At 2024-12-3111,319,642USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-09-30197,851USD
At 2024-12-3138,298USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-09-30198,583USD
At 2024-12-3139,323USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2025-09-3037,472,621USD
At 2024-12-3136,981,797USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2025-09-3032,970,142USD
At 2024-12-3132,098,396USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2025-09-308,775,036USD
At 2024-12-316,695,436USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2025-09-30170,426USD
At 2024-12-31247,159USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

PeriodValueUnitDays
At 2025-09-30120,912USD
At 2024-12-31162,208USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2025-09-3022,700,000USD
At 2024-12-3121,700,000USD

Net deferred tax liabilities

Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.

PeriodValueUnitDays
At 2025-09-30739,733USD
At 2024-12-31731,202USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-651,482USD92
2025-01-01 to 2025-09-30-1,965,421USD273
2024-07-01 to 2024-09-30-1,117,911USD92
2024-01-01 to 2024-09-30-3,511,933USD274

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-594,147USD92
2025-01-01 to 2025-09-30-1,880,307USD273
2024-07-01 to 2024-09-30-980,273USD92
2024-01-01 to 2024-09-30-3,441,372USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30424,827USD92
2025-01-01 to 2025-09-301,372,843USD273
2024-07-01 to 2024-09-30345,051USD92
2024-01-01 to 2024-09-30925,377USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2025-07-01 to 2025-09-30158,076USD92
2025-01-01 to 2025-09-30592,099USD273
2024-07-01 to 2024-09-30493,180USD92
2024-01-01 to 2024-09-301,863,079USD274

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2025-01-01 to 2025-09-301,006,210USD273
2024-01-01 to 2024-09-302,169,993USD274

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2025-07-01 to 2025-09-30197,958USD92
2025-01-01 to 2025-09-30513,030USD273
2024-07-01 to 2024-09-30104,845USD92
2024-01-01 to 2024-09-30306,914USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-23,337USD92
2025-01-01 to 2025-09-3073,462USD273
2024-07-01 to 2024-09-30-32,654USD92
2024-01-01 to 2024-09-30-119,103USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-01-01 to 2025-09-3059,040USD273
2024-01-01 to 2024-09-3065,468USD274

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2025-07-01 to 2025-09-3019,119USD92
2025-01-01 to 2025-09-3059,025USD273
2024-07-01 to 2024-09-3021,061USD92
2024-01-01 to 2024-09-3061,135USD274

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-379,210USD273
2024-01-01 to 2024-09-30-1,095,892USD274

Inspect the source

Entity
CHINA PHARMA HOLDINGS, INC. / CIK 0001106644
Captured
2026-09-20T05:23:28.377Z
SEC response SHA-256
ad45dffd15d0f5a098ab8b6912816a8b1b845b1d791781ea412833d3178873c0

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001106644.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))